The effect of cardiopulmonary bypass on Maresin-1 levels and implications for cardiac function

Abstract

Aim: Cardiopulmonary bypass (CPB) surgery causes changes in biomarkers associated with inflammatory responses and cardiac stress. Maresin-1 is a novel lipid mediator involved in inflammation resolution, and its role in cardiac function and its prognostic value postoperatively have not yet been sufficiently investigated. The aim of this study is to investigate the effect of CPB on Maresin-1 levels and to comparatively evaluate the prognostic value of Maresin-1 in the pathophysiology of coronary artery disease.

Methods: Eighty patients were included in this study. Maresin-1 levels were investigated in 40 patients before surgery (group 1) and after surgery (group 2). The other 40 individuals included in the study formed the healthy control group. Maresin-1 and NT-proBNP levels were measured in the preoperative and postoperative periods. The data were evaluated comparatively using the Wilcoxon test and ROC analysis.

Results: Preoperative Maresin-1 levels were significantly higher than those in the control group (p < 0.001). Postoperative Maresin-1 levels decreased markedly
(p < 0.001); however, no significant difference was detected between postoperative Maresin-1 levels in the control group (p = 0.942). ROC analysis demonstrated that Maresin-1 and NT-proBNP possess high discriminatory power in distinguishing patients with coronary artery disease from healthy controls (AUC: 0.918 and 0.923)

Conclusion: Maresin-1 levels significantly increase before CPB and decrease significantly in the early post-CPB period, reflecting pathophysiological changes in cardiac function. Maresin-1 can be considered a complementary biomarker with prognostic potential in patients undergoing CPB, compared with NT-proBNP.